Gadget guru @ijustine began streaming back in the webcam days. Today, she is a leading voice in the tech industry. Her YouTube channel boasts more than 7 million subscribers who tune in for her reviews. #ForbesTopCreators (Photo: Cody Pickens for Forbes) https://t.co/emUFJXknXp https://t.co/GxjpMdizY9 ...

"你好，欢迎来到龙岗！"线上的手语老师通过音书政务无障碍系统，将语音实时转化为手语画面，听障 人士得以"读懂"问候。 龙岗区企业音书科技研发的音书政务无障碍系统，依托实时在线翻译功能，通过设备一键连接专业手语 老师，以视频通话的形式实现语音与手语的即时转换，为赛事咨询、流程指引等场景提供高效无障碍沟 通服务。 7月1日至8日，残特奥会自行车赛在深圳龙岗举行。 "本届残特奥会将以办赛为契机，进一步推动科技助残事业发展。"残特奥会自行车竞赛委员会观众服务 处副处长、龙岗区残疾人服务中心主任陈汝婷介绍。 据了解，龙岗区主要从"科技助残"与"人文关怀"两个维度入手，联合了38家科技企业，精选手语翻译 器、导盲兔AI眼镜等108项优质产品，覆盖运动保障、生活服务、无障碍出行等各类场景。 这一次残奥会是检验龙岗科技助残成果的"超级舞台"，其谋局并不止于本次赛事，更在为之后即将到来 的十五运会和残特奥会赛事积累赛事经验。 科技办赛让龙岗辖区内企业有了技术验证平台，灵锶智能的四足机器狗与鑫龙浩的轮式无人巡逻车形成 的"地面防线"，配合公安部门开展24小时无死角巡逻巡查。 这些来自实战场景的运行参数，有助于企业进一步优化算法， ...

UAE proptech Huspy raises $59M to scale in Europe | TechCrunch https://t.co/OmMdvpfIUj ...

Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update June 10, 2025 Legal Notices The information in this slide deck is current as of June 10, 2025, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in this presentation about future expectations, plans and ...

COMBINING TO CURE ® Forward-Looking Statements/Safe Harbor Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in t ...

Broadridge's instructing party model developed in collaboration with the European Central Bank's TIPS system, has been a key factor in client adoption, significantly reducing costs, simplifying compliance and minimizing time to market. "With the October 2025 deadline for full compliance approaching, banks are under pressure to meet instant payment requirements," said Heidi Dittmar, managing director of Swift Services, Broadridge. "Working with Broadridge has enabled our customers to integrate real-time paym ...

Apple’s Top AI Exec Leaves for Meta Amid Aggressive Hiring Trend► https://t.co/VOGBfbkjlU https://t.co/VOGBfbkjlU ...

齐鲁晚报·齐鲁壹点 夏侯凤超 历下区委副书记、代区长赵治文介绍，历下区重点产业不断壮大。历下区着力汇聚核心要素资源，精心 构建协同发展生态，全力推动电子信息、现代医药两大重点产业集群发展。在电子信息产业方面，通过 龙头企业的引领不断提升发展能级。作为电子信息产业的重点行业，2024年，全区软件产业规模达到 800亿元，同比增长15%以上，重点企业中创中间件成功上市，瑞泉电子、泰华智慧等150余家优质企业 入驻山东人工智能产业园、明湖国际信创产业园，信创产业获评山东省"雁阵型"产业集群。在现代医药 产业方面，逐步构建起特色鲜明的产业生态。加快布局细胞与基因治疗等特色前沿产业，丽山国际细胞 医学产业园、生物制药生产基地建成高标准厂房30万平方米，配套建设了细胞CDMO和公共实验平台， 引进了第三方检测认证服务机构，吸引中源协和（600645）、骏腾医疗、华测检测（300012）等60家优 质企业入驻发展。 发展质效持续提升。历下区始终坚持向质量要效益，全区现有规模以上工业企业49家，2024年完成规上 工业总产值422亿元，近三年平均增速超过10%。在保持平稳健康增长的同时，产业结构不断优化， 二、三产业比重调整 ...

Core Viewpoint - Diginex Limited has proposed an eight-for-one forward stock split to enhance shareholder accessibility and liquidity, with the aim of broadening its investor base and supporting long-term growth [1][4]. Group 1: Stock Split Details - The Board of Directors has scheduled an extraordinary general meeting on July 29, 2025, for shareholders to vote on the proposed forward stock split and related amendments [2]. - If approved, each ordinary share of US$0.00005 par value will be subdivided into eight ordinary shares of US$0.00000625 par value each, and the same subdivision will apply to preferred shares [3]. - The authorized share capital will be adjusted to US$50,000, divided into 7,680,000,000 ordinary shares and 320,000,000 preferred shares, with fractional shares rounded up [3]. Group 2: Company Overview - Diginex Limited is a leading provider of Sustainability RegTech solutions, focusing on ESG, climate, and supply chain data collection and reporting [5]. - The company utilizes advanced technologies such as blockchain, AI, and machine learning to enhance transparency in corporate regulatory reporting and sustainable finance [5]. - Diginex's diginexESG platform supports 17 global frameworks, providing comprehensive support for clients in sustainability data management and reporting [6].

Core Viewpoint - Ascentage Pharma Group International has appointed Veet Misra, Ph.D., as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance, aiming to accelerate its global growth strategy in the biopharmaceutical sector [1][2][3] Management Appointments - Dr. Veet Misra brings over 20 years of investment banking experience, particularly in the biopharmaceutical sector, and holds a Ph.D. in Molecular Biology and an MBA in Finance & Strategy [4][5] - Mr. Eric Huang has over 20 years of experience in the global pharmaceutical industry, previously serving as CFO for Greater China and Asia-Pacific at Beigene, and holds an MBA in Finance [5] Company Strategy and Growth - The company is entering a notable growth phase, with the new executives expected to enhance its global strategy and operational excellence [2][3] - Ascentage Pharma is focused on becoming a leading fully integrated global biopharmaceutical company, leveraging its dual listing on the Hong Kong Stock Exchange and Nasdaq [2][4] Product Pipeline - Ascentage Pharma has a robust pipeline of innovative drug candidates targeting cancers, including apoptosis-targeted therapies and next-generation kinase inhibitors [6][7] - The lead asset, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for specific types of chronic myeloid leukemia (CML) and is undergoing global Phase III trials [8] - Another key asset, lisaftoclax, is a Bcl-2 inhibitor for hematologic malignancies, with its NDA accepted for Priority Review in China and multiple global Phase III trials ongoing [9] Partnerships and Collaborations - The company has established partnerships with leading pharmaceutical firms such as Takeda, AstraZeneca, Merck, and Pfizer, enhancing its research and development capabilities [10]